Skip to main content
Fig. 6 | BMC Cancer

Fig. 6

From: Vorinostat enhances the cisplatin-mediated anticancer effects in small cell lung cancer cells

Fig. 6

Antitumor activity of combined vorinostat and cisplatin in H209 xenografts. Immunodeficient nude mice bearing subcutaneously established H209 xenograft tumors were randomized to 4 groups and received the indicated treatments: (I) vehicle, (II) vorinostat (dosage of 40 mg/kg body weight, administered 4 times a week), (III) cisplatin (dosage of 1.5 mg/kg body weight, administered once a week), and (IV) combination (cisplatin at a dosage of 1.5 mg/kg body weight, administered once a week; vorinostat at a dosage of 40 mg/kg body weight, administered 4 times a week) through intraperitoneal injection. The therapy was started in an initial volume of 100 mm3 and tumors were measured regularly. a Tumor growth curves were expressed as mean ± SD with the T/C% at day 5. b Tumor volumes in each group were shown at day 5. A significant inhibition in tumor growth was documented (***, P < 0.001) compared with that in vorinostat or vehicle

Back to article page